Actelion Pharmaceuticals launches Epoprostenol for Injection for treatment of primary pulmonary hypertension Actelion Pharmaceuticals US, Inc. Today announced the industrial option of Epoprostenol for Injection, an improved formulation of epoprostenol that’s stable at room heat, for the treating main pulmonary hypertension and pulmonary hypertension connected with scleroderma spectral range of disease in NYHA Class III and Course IV patients. Simultaneously, the ongoing firm has launched the chance registry, a multicenter, observational, U.S.-based registry that will provide additional clinical experience on patients being treated with Epoprostenol for Injection. Epoprostenol for Injection is definitely a therapy accepted by the U.S.We also need a coordinated international approach to reduce the disparity in time to gain access to new drugs around the world. Commenting on the study, Professor David Cameron, director of the Edinburgh Cancer Research Centre, UK, noted: This interesting study compares the times to regulatory authorization in USA, Canada and Europe. There was little difference general between the approval situations for the EMA and Health Canada, but both these agencies approved brand-new anti-cancer agents later compared to the FDA in USA significantly. Interestingly one drug, carbazitaxel, was approved in under 1 month in the USA. It is not clear why there were these differences, however they are of some concern in the sense that they suggest that in the absence of data to the contrary, there may be bureaucratic instead of medical/scientific known reasons for differential geographical authorization timelines –which of training course will lead to differential geographical benefits from new agents, Cameron said.